Amisulpride endocrine

The results of 11 studies in 1933 patients with schizophrenia, who were randomly assigned to amisulpride (n = 1247), haloperidol (n = 309), risperidone (n = 113), flupenthixol (n = 62), or placebo (n = 202) have been reviewed (45). Extrapyramidal signs occurred in 15% of those given amisulpride (n = 579), 12% of those given risperidone (n = 113), and 31% of those given haloperidol (n = 214). In contrast, endocrine disorders were more frequent with amisulpride (4%) and risperidone (6%) than with haloperidol (1%). In a subgroup of patients with predominant negative schizophrenia who had at... 

Amisulpride 600-1200 mg/day for 3 months was effective and well tolerated in 445 patients with schizophrenia aged 18 15 years (1). During this time, 124 patients (28%) dropped out of the study 21% reported adverse events, neurological (35%), psychiatric (15%), or endocrine (9.1%). Seven adverse events were assessed as serious two suicides, two suicide attempts, one neuroleptic malignant syndrome, one somnolence, and one worsening of arteritis. 

In a randomized double-blind study, there were no differences in the numbers of patients with at least one adverse effect with amisulpride 100 mg (24% n = 18), amisulpride 50 mg (25% n = 21), or placebo (33% n = 27) (5). Few patients had endocrine symptoms (2 out of 160 in the amisulpride groups). 

---